Company intelligence / Profile preview

GeneHarmonics

California/Texas, United Statesgeneharmonics.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

GeneHarmonics has developed validated prototypes of rapid point-of-care diagnostic devices capable of delivering laboratory-quality results for multiple biomarkers within 15 minutes. These have been validated using FDA-approved protocols. The foundational Quantum Dot technology enables rapid adaptation to new applications and supports a secure AI/ML-powered data platform for biomarker trend analysis. Regulatory compliance kits and commercial launch plans are underway

Modalities: Diagnostic deviceQuantum Dot-based diagnosticsData platform for biomarker monitoring
Industry: Molecular Diagnostics

Partnerships

Several pharmaceutical companies (undisclosed) for drug delivery system development and clinical trials leveraging their diagnostics/data techCollaborations with Asian/U.S.-based partners in biotech/pharma sectors

Beyond the preview

Go deeper on GeneHarmonics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeneHarmonics.

Explore the full profile